No everyone is cool. My brother sold at $16 or so on the way back down. He was in around $9-10, and actually pulled 100% out of the market when he sold ADXS. He's happy. We will rock in 2016, of that I'm sure.
BTW HALO was in the $6's during the hold and now trade at nearly $18. Actually traded up to about $23 or so a few months ago. Relative to HALO's market cap ( just like ADRO's mc ) we are soooo cheap right now....
lifted. IMO these thing usually take 2 -3 months to be resolved. We know it will be lifted soon and I expect the price to creep up beforehand. Because of this hold i now own more than I ever did on the first run up. IMHO we will trade well north of $40 in 2016. Happy Thanksgiving all.
From the article:Anavex Life Sciences Corp. is also aware that beta-amyloid peptides are the root cause of AD symptoms. Rather than deal with the symptom though (which may continually resurface no matter how much they're treated), AVXL is going straight to the heart of the problem; its drug may circumvent the need to remove beta plaques from the brain in the first place... a removal that would never be complete anyway.
Recent research has verified that oxidative stress is a precursor to amyloid-beta plaques and tau (aka Neuro-Fibrillary Tangles or NFT). By protecting against oxidative stress in the first place, such a drug may help to prevent or slow Alzheimer's disease before it has a chance to develop.
To that end, Anavex Life Sciences has developed ANAVEX 2-73 - a therapy that jives with the description above, and one that just completed Phase I trials. The drug has shown great promise due to its efficacy in validated animal models, no toxicity to date in exhaustive this animal testing, and a mode of action that blunts endoplasmic reticulum (ER) stress, mitochondrial stress, and most importantly, staves off oxidative stress that could be the bigger underlying Alzheimer's.
Perhaps even more important to investors now, however, is that AVXL is starting to grab the attention of other investors, and getting bullish traction as a result. A downtrend that had plagued the stock for the bulk of 2011 has turned into an uptrend. More than that, the buying volume has started to perk up as of this week.